Effect of Baricitinib Treatment on Peripheral Bone in RA

Sponsor
University of Erlangen-Nürnberg Medical School
Study ID
NCT03701789
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 74 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib — DRUG
    Effect of Baricitinib on vBMD measured by HR-pQCT

Study Details

Patients with Rheumatoid Arthritis (RA) suffer systemic and peripheral bone loss. In this study we aim to test the efficacy of in-label treatment with Baricitinib on the volumetric bone mineral density in patients with RA over 52 weeks. Inclusion of RA patients comprises pathologic volumetric bone mineral density measured by (High Resolution peripheral quantitative Computed Tomomgraphy) HR-pQCT maging of finger joints.

Key Dates

Start date
Sep 11, 2018
Status verified
Jan 2021
Primary completion
Oct 11, 2021
Completion
Oct 11, 2021

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Patients with Rheumatoid Arthritis
    In-label treatment with Baricitinib

Primary Outcome Measure

Change in volumetric bone mineral density (vBMD) in metacarpal and radial bone between baseline and week 52 in patients with rheumatoid arthritis treated with baricitinib as determined by HR-pQCT [ Time Frame: 52 weeks ]

Related Studies